The company also forecasts FY26 adjusted net income of $25M-$45M and adjusted EBITDA of $135M-$155M. “Our team remains focused on long-term sustainable value and achieving our vision of enabling several durable and profitable verticals in the Company over time,” said CEO Joe Papa.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions sees Q1 revenue $135M-$155M, consensus $275M
- Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year
- Emergent BioSolutions announces up to C$140M in Canadian contracts
- Emergent BioSolutions authorizes $50M stock repurchase program
- Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround